Creative Planning Raises Stock Position in Hologic, Inc. $HOLX

Creative Planning grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 229.8% in the second quarter, Holdings Channel.com reports. The fund owned 73,122 shares of the medical equipment provider’s stock after purchasing an additional 50,953 shares during the period. Creative Planning’s holdings in Hologic were worth $4,765,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Capital Investment Counsel Inc raised its holdings in Hologic by 2.6% during the second quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider’s stock worth $379,000 after purchasing an additional 150 shares during the last quarter. Greenleaf Trust increased its position in shares of Hologic by 5.1% in the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after buying an additional 173 shares in the last quarter. Savant Capital LLC raised its stake in shares of Hologic by 1.2% during the 2nd quarter. Savant Capital LLC now owns 19,606 shares of the medical equipment provider’s stock worth $1,278,000 after buying an additional 232 shares during the last quarter. First American Bank boosted its position in shares of Hologic by 0.9% in the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock worth $1,870,000 after buying an additional 245 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its stake in Hologic by 1.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,788 shares of the medical equipment provider’s stock valued at $964,000 after acquiring an additional 246 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on HOLX. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. UBS Group lifted their price objective on Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. BNP Paribas Exane lowered Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 target price on the stock. in a research note on Friday. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Friday, October 31st. Finally, Evercore ISI set a $78.00 price objective on Hologic and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Five research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $79.67.

Hologic Trading Up 0.3%

Shares of Hologic stock opened at $74.36 on Friday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $80.31. The firm has a market cap of $16.54 billion, a PE ratio of 30.85, a P/E/G ratio of 2.54 and a beta of 0.65. The business’s fifty day moving average is $70.59 and its two-hundred day moving average is $66.30. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the previous year, the business earned $1.01 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.